Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Bio-Reference Laboratories Inc (NASDAQ: BRLI) acted responsibly on behalf of investors’ profitability in the planned $1.47 billion sale to Opko Health Inc (NYSE: OPK).

On June 4, 2015, Bio-Reference Laboratories Inc (NASDAQ: BRLI) and Opko Health Inc (NYSE: OPK) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Bio-Reference  shareholders will receive 2.75 shares of Opko common stock for each share of BRLI common stock. Based on a closing price of $19.12 per share of Opko common stock on June 3, 2015, the transaction is valued at approximately $1.47 billion, or $52.58 per share of BRLI common stock.

Based in Elmwood Park, NJ, and founded in 1981 Bio-Reference Laboratories Inc is a provider of clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in the United States.  It serves physicians, geneticists, hospitals, clinics, and correctional and other health facilities. 

The investigation focuses on whether NASDAQ: BRLI investors received the highest price and whether the directors of Bio-Reference Laboratories Inc acted in the best interest of Bio-Reference Laboratories Inc company and its shareholders.   

If you purchased Bio-Reference Laboratories Inc (NASDAQ: BRLI) prior to June 4, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324. 

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185